Experimental Weight Loss Injection Dramatically Relieves Knee Osteoarthritis Pain
An experimental weekly weight-loss injection, retatrutide, significantly reduced knee osteoarthritis pain and improved mobility in clinical trials, eliminating pain for one in eight patients.

An experimental weekly injectable medication designed for weight loss has demonstrated significant efficacy in reducing chronic knee pain and improving mobility among patients suffering from knee osteoarthritis and obesity. According to the findings of two phase 3 clinical trials, which evaluated the investigational drug retatrutide, researchers observed that weight reduction directly correlated with a marked decrease in joint discomfort. The studies, which encompassed a combined total of 1,019 adult participants, revealed that roughly two-thirds of those receiving the treatment experienced a pain reduction of at least 50%, compared to 38% in the placebo group.
Clinical Trial Findings and Weight Reduction
The research results, published in The New England Journal of Medicine, highlighted unprecedented outcomes regarding both weight loss and pain alleviation. In the first trial involving 445 individuals monitored over 68 weeks, patients receiving a 9 mg dose of retatrutide lost an average of 20% of their body weight, while those on a 12 mg dose achieved a 23.7% weight reduction, contrasted with a 4.6% loss in the placebo cohort. Furthermore, approximately one in eight patients who received the experimental treatment reported that their knee pain vanished entirely. Aside from joint relief, the trials documented improvements in blood pressure, blood lipid profiles, and systemic inflammation markers, although gastrointestinal side effects were reported as the most frequent adverse reactions.
Medical Insights and Mechanism of Action
Retatrutide functions by targeting the receptors of three distinct hormones involved in appetite regulation and metabolism: GLP-1, GIP, and glucagon. Funded by Eli Lilly and Company, the developer of the therapeutic compound, the studies focused on patients with a body mass index (BMI) of 27 or higher without diabetes. Dr. Alex Geftler, an orthopedic specialist at Maccabi Healthcare Services in the South, noted that while the reduction in physical load on weight-bearing joints largely explains the symptom relief, researchers are investigating whether the medication possesses independent anti-inflammatory properties that directly impact joint tissues.
Future Applications and Limitations
Despite the promising results, the medication remains experimental and has not yet received approval from the U.S. Food and Drug Administration (FDA). Medical professionals emphasize that the treatment is primarily suited for patients with moderate osteoarthritis and obesity whose condition has not advanced to bone-on-bone friction or required surgical joint replacement. Experts stress that further long-term monitoring is necessary to determine whether retatrutide can genuinely halt disease progression, prevent cartilage degradation, or potentially delay the necessity for total knee replacement surgeries.


